Land: Nederland
Taal: Nederlands
Bron: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
LEVETIRACETAM
Fair-Med Healthcare GmbH Planckstraße 13 22765 HAMBURG (DUITSLAND)
N03AX14
LEVETIRACETAM
Filmomhulde tablet
CROSPOVIDON (E 1202) ; HYPROMELLOSE (E 464) ; IJZEROXIDE ROOD (E 172) ; MACROGOL 400 ; MAGNESIUMSTEARAAT (E 470b) ; POVIDON K 30 (E 1201) ; SILICIUMDIOXIDE (E 551) ; TALK (E 553 B) ; TITAANDIOXIDE (E 171) ; ZONNEGEEL FCF ALUMINIUMLAK (E 110),
Oraal gebruik
Levetiracetam
Hulpstoffen: CROSPOVIDON (E 1202); HYPROMELLOSE (E 464); IJZEROXIDE ROOD (E 172); MACROGOL 400; MAGNESIUMSTEARAAT (E 470b); POVIDON K 30 (E 1201); SILICIUMDIOXIDE (E 551); TALK (E 553 B); TITAANDIOXIDE (E 171); ZONNEGEEL FCF ALUMINIUMLAK (E 110);
2012-02-08
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT _ _ LEVETIRACETAM FAIR-MED HEALTHCARE 250 MG, FILMOMHULDE TABLETTEN LEVETIRACETAM FAIR-MED HEALTHCARE 500 MG, FILMOMHULDE TABLETTEN LEVETIRACETAM FAIR-MED HEALTHCARE 750 MG, FILMOMHULDE TABLETTEN LEVETIRACETAM FAIR-MED HEALTHCARE 1000 MG, FILMOMHULDE TABLETTEN Levetiracetam READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet .See section 4. _ _ WHAT IS IN THIS LEAFLET: 1. Whatis and what it is used for 2. What you need to know before you take Lees het volledige document3. How to take 4. Possible side effects 5. How to store 6. Contents of the pack and other information 1. WHAT IS AND WHAT IT IS USED FOR film-coated tabltes are an antiepileptic medicine (a medicine used to treat seizures in epilepsy). is used alone in the treatment of partial seizures in patients from 16 years of age. is used in patients who are already taking another antiepileptic medicine_ _ in the treatment of partial seizures in adults, children and infants from 1 month age in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE DO NOT TAKE If you are allergic ( hypersensitive) to levetiracetam or any of the other ingredients of this medicine (listed in Section 6). WARNINGS AND PREC
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Levetiracetam Fair-Med Healthcare 250 mg, filmomhulde tabletten Levetiracetam Fair-Med Healthcare 500 mg, filmomhulde tabletten Levetiracetam Fair-Med Healthcare 750 mg, filmomhulde tabletten Levetiracetam Fair-Med Healthcare 1000 mg, filmomhulde tabletten 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 250 mg levetiracetam. Each film-coated tablet contains 500 mg levetiracetam. Each film-coated tablet contains 750 mg levetiracetam. Each film-coated tablet contains 1000 mg levetiracetam. Excipients: 750 mg:film-coated tablets contains 0.375 mg Sunset Yellow Aluminium Lake (E110) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. 250 mg: Blue, oval shaped film coated tablets with a break line on one side with dimensions 12.9 x 6.1 mm. The tablet can be divided into equal halves. 500 mg: Yellow, oval shaped film coated tablets with a break line on one side with dimensions 16.5 x 7.7 mm. The tablet can be divided into equal halves. 750 mg: Orange, oval shaped film coated tablets with a break line on one side with dimensions 18.8 x 8.9 mm. The tablet can be divided into equal halves. 1000 mg: White, oval shaped film coated tablets with a break line on one side with dimensions 19.2 x 10.2 mm. The tablet can be divided into equal halves. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Lees het volledige documentis indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents, children and infants from 1 month of age with epilepsy. in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. in the treatment of primary generalised